Valuation: AtheroNova Inc.

Market Cap 2.47M 2.16M 2.02M 1.85M 3.48M 236M 3.54M 23.91M 9.36M 117M 9.26M 9.06M 404M P/E 2012
-4.89x
P/E 2013 -1.93x
Enterprise Value 2.95M 2.59M 2.41M 2.22M 4.16M 282M 4.23M 28.64M 11.21M 140M 11.09M 10.85M 483M EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Director TitleAgeSince
Director/Board Member 54 02/01/2012
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 9.69K
+0.14%-0.85%-1.20%+11.73% 47.74B
-2.24%+1.92%+385.05%+630.47% 39.98B
+1.40%+6.40%+13.38%+57.74% 36.23B
+13.94%+19.15%+21.98%+8.18% 35.59B
-0.73%+2.78%+4.65%+41.16% 27.91B
+0.40%+1.06% - - 16.71B
-3.12%+8.15%+27.59%+129.42% 16.45B
+2.39%-3.63%-0.35%+10.34% 13.21B
+6.79%+8.46%-3.62%-25.41% 12.93B
Average +2.03%+2.50%+55.93%+107.95% 24.68B
Weighted average by Cap. +2.34%+2.95%+74.49%+135.78%

Financials

2012 2013
Net sales - -
Net income -2.64M -2.31M -2.15M -1.98M -3.71M -252M -3.78M -25.55M -10M -125M -9.89M -9.68M -431M -7.81M -6.86M -6.39M -5.87M -11.01M -747M -11.2M -75.77M -29.66M -370M -29.34M -28.7M -1.28B
Net Debt -2.38M -2.09M -1.95M -1.79M -3.36M -228M -3.42M -23.11M -9.04M -113M -8.95M -8.75M -390M 487K 427K 398K 366K 686K 46.53M 698K 4.72M 1.85M 23.08M 1.83M 1.79M 79.73M
Logo AtheroNova Inc.
AtheroNova Inc is a United States-based biopharmaceutical company. The Company through its subsidiary is focused on the research and development of compounds to regress atherosclerotic plaque and improve lipid profiles in humans. The Company develops various applications for its compounds to be used for the treatment of atherosclerosis. The Company's development products include AHRO-001 and AHRO-002. The Company's pipeline candidates include applications for the treatment of localized reduction of subcutaneous fat deposits through transdermal application, obesity, hypertension, diabetes and Peripheral Artery Disease (PAD). The Company's lead compound is AHRO-001. Through the process of reverse cholesterol transport, the compound is designed to dissolve plaque within the walls of the arteries and removes it from the body through natural metabolic processes. AHRO-001 and AHRO-002 are orally administered compounds.
Employees
-
  1. Stock Market
  2. Stocks
  3. AHROQ Stock